Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up cohort

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a 5-year survival rate of <7%. Carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) are often used to predict the outcome of the malignancy independently. However, the joint prognostic effect of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Guofeng, Liu, Xiaoyu, Wang, Xiaoyi, Jin, Dayong, Chen, Yi, Li, Guoping, Li, Changyu, Fu, Deliang, Xu, Wanghong, Wang, Xiaolin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338972/
https://www.ncbi.nlm.nih.gov/pubmed/28280354
http://dx.doi.org/10.2147/OTT.S116136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338972/
https://www.ncbi.nlm.nih.gov/pubmed/28280354
http://dx.doi.org/10.2147/OTT.S116136

Ejemplares similares